News and events

March 10, 2020

Today we have received the concerning news from QSPC2020 organizers about the cancellation of the conference in response to COVID-19 outbreak continuation. Quantitative Systems Pharmacology Conference 2020 was planned to be held in April 22-24, 2020 Leiden, The Netherlands. InSysBio team was prepared to present 10 posters

13th InSysBio Annual Internal Scientific Meeting

March 3, 2020

26-28 February 2020 InSysBio QSP-company held its 13th Annual Internal Scientific Meeting. InSysBio team presented the results of 2019 year professional progress. Every member demonstrated their personal achievements and shared the plans for the future development. Oleg Demin, InSysBio CEO and founder, summarized all the company’s advancement of the year 2019.

InSysBio presents an enhanced version of its Immune Response Template Database

PRESS-RELEASE

SOFTWARE

February 21, 2020

IRT Version 3.0.0 acquires a wide variety of updates and new options

(Moscow – 21.02.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) platform development and provision, moves forward to the future.

InSysBio to participate in ASCPT 2020

February 19, 2020

InSysBio announced its participation in 121st Annual meeting of American Society for Clinical Pharmacology and Therapeutics (ASCPT 2020) which is to be held on March 18-21, 2020 at Marriott Marquis Houston, TX. InSysBio welcomes visitors at the booth # 102. Oleg Demin, CEO of InSysBio, Tatiana Karelina, lead modeler in Alzheimer's Disease and Veronika Musatova, Head of IRT development team, will present the new version of IRT (Immune Response Template) and Cytocon DB (Cell and cYTOkine CONcentrations).

InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting

December 3, 2019

QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.

PK/RO simulator for anti-PD-1 mAbs

SOFTWARE

PRESS-RELEASE

November 25, 2019

InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.

Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics

education

November 18, 2019

This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.

InSysBio continues the training course “Modeling for systems biology and biomedicine”

education

September 26, 2019

InSysBio expert modelers Dr Tatiana Karelina and Dr Evgeny Metelkin will give the course “Modeling for systems biology and biomedicine” at the Faculty of physics, Lomonosov Moscow State University.

InSysBio to present at SITC 2019

September 24, 2019

InSysBio announces their participation at 34th Annual Meeting & Pre-Conference Programs on Systems Biology (SITC 2019)

InSysBio to present at ACoP10

September 18, 2019

InSysBio announces their participation at Tenth American Conference on Pharmacometrics (ACoP10) to be held October 20th to 23rd, 2019, at the Rosen Shingle Creek Hotel in Orlando, FL.